Novo Nordisk is investing $306 million in a new facility in Hillerød, Denmark. The facility will produce medicines for the treatment of diabetes and obesity.

The facility is expected to be operational in 2019 and will create 450 new production and engineering jobs in Hillerød, where Novo Nordisk already employs 1,900 people. Incorporating the latest state-of-the-art insulin production technology, the new insulin filling facility will ensure production capacity for existing and future products within diabetes.